Merck, Schering-Plough End Vytorin Investigation

Law360, New York (July 15, 2009, 12:00 AM EDT) -- In a settlement, Merck & Co. and Schering-Plough Corp. have agreed to reimburse 35 states and the District of Columbia for the costs associated with investigating a delay in the companies' release of negative results of a clinical trial of the jointly marketed cholesterol treatment Vytorin.

The deal announced Wednesday by the states and the companies also calls for Merck and Schering-Plough to obtain preapproval from the U.S. Food and Drug Administration for all direct-to-consumer television advertisements and to comply with FDA suggestions to modify drug...
To view the full article, register now.